ArticleRecent patents on nanotechnology2023
Formulation and Characterization of Self-Microemulsifying Drug Delivery System (SMEDDS) of Sertraline Hydrochloride.
Article in Recent patents on nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- A reduction-sensitive lipophilic dihydroartemisinin prodrug in a self-microemulsifying drug delivery system for treating breast cancer lung metastasis via intestinal lymphatic transport.International journal of pharmaceutics: X · 2026Article
- Recent Advancements in Nanoparticles-based Approaches for the Theranostics of Glioblastoma Multiforme.Current pharmaceutical biotechnology · 2026Review
- Recent Advances in Artificial Intelligence and Nanotechnology-Driven Strategies for Diagnosis and Therapy of Ocular Diseases.Current drug delivery · 2026Review
- Formulation Development of Natural Polymeric Nanoparticles, In Vitro Antiaging Evaluation, and Metabolite Profiling ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Design Optimization and Evaluation of Patented Fast-Dissolving Oral Thin Film of Ambrisentan for the Treatment of Hypertension.Recent patents on nanotechnology · 2025Article
- Sustained Delivery of Dolutegravir Sodium for Better Management of HIV/AIDSCurrent HIV research · 2025Article
- Formulation Optimization and Characterization of Solid Lipid Nanoparticles of Apixaban.Recent patents on nanotechnology · 2025Article
- Design and Characterization of Chitosan-Based Smart Injectable Hydrogel for Improved Sustained Release of Antinarcotics.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSertraline hydrochloride is the most widely used selective serotonin reuptake inhibitor (SSRI) for treating several depressive disorders. The applicability of Sertraline hydrochloride is limited due to the extensive metabolism and poor oral bioavailability of 44%.
objectiveThe current research focused on improving the solubility and oral bioavailability of Sertraline in the form of microemulsion developed by a self-micro emulsifying drug delivery system (SMEDDS) for significant antidepressant action.
methodsSMEDDS were developed by selecting appropriate proportions of oil, surfactant, and cosolvent, and out of them, isopropyl myristate, tween 80, and propylene glycol were selected. The emulsification zone was demonstrated by a ternary phase diagram, and the compatibility was confirmed with Fourier-transformed infrared spectroscopy (FT-IR). The formulated SMEDDS was characterized by the robustness to dilution, globule size (GS), polydispersity index (PDI), viscosity,
resultsAll the batches (A1-A9) passed the quality test, and A3 was selected as an optimized batch that doesn't show phase separation and precipitation. The optimized batch A3 showed globule size (101 nm), PDI (0.319), drug content (99.14 ± 0.35%), viscosity (10.71 ± 0.02 mPa), self-emulsification time (46 sec),
conclusionAn optimized batch A3 was observed, which was circular in shape and estimated by Transmission electron microscopy (TEM), passing all the thermodynamic stability testing with a loss of 0.271 mg of the drug after 90 days, and showed marked antidepressant action with higher stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.